| Business Summary | | Genetronics
Biomedical
Corporation,
formerly
known
as
Genetronics
Biomedical
Ltd.,
is
a
drug
and
gene
delivery
company
specializing
in
developing
technology
and
hardware
focused
on
electroporation.
Electroporation
is
the
application
of
brief,
controlled
pulsed
electric
fields
to
cells,
which
cause
tiny
pores
to
temporarily
open
in
the
cell
membrane.
The
Company
conducts
business
through
its
operating
subsidiary
Genetronics,
Inc.
The
Company
operates
through
two
divisions:
the
Drug
and
Gene
Delivery
Division,
through
which
the
Company
is
developing
drug
and
gene
delivery
systems
based
on
electroporation
to
be
used
in
the
treatment
of
disease;
and
the
BTX
Instrument
Division,
which
develops,
manufactures,
and
sells
electroporation
equipment
to
the
research
laboratory
market
for
in
vitro
and
for
in
vivo
animal
experimentation. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | GEB
develops,
manufactures,
and
markets
electroporation
instrumentation
and
accessories
used
to
perform
genetic
engineering
techniques,
such
as
cell
fusion,
gene
transfer,
cell
membrane
research
and
genetic
mapping.
For
the
three
months
ended
6/30/01,
revenues
fell
38%
to
$899
thousand.
Net
loss
before
accouting
change
rose
38%
to
$2.7
million.
Revenues
reflect
lower
sales
due
to
the
economic
decline.
Net
loss
also
reflects
an
increase
in
salary
related
expenses. | More
from
Market Guide: Significant
Developments |
| | |
| Position | James Heppell, 44 | Interim
Chairman | Grant Denison, Jr., 50 | Pres,
CEO, Director | Mervyn McCulloch, 57 | CFO | Terry Gibson | COO | Babak Nemati, Ph.D. | VP,
Corp. Devel. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|